Panel Discussion: Perspectives from Patients & Prescribing Neurologists on the Clinical Adoption of Disease-Modifying Anti-Amyloid Therapeutics
Time: 9:00 am
day: Conference Day Two AM
Details:
- What is the patient burden associated with anti-amyloid therapies and how might these treatments be improved?
- What are the key factors driving Lecanemab and Donanemab uptake among patients?
- What are the hesitancies from prescribing neurologists to adapt to these new therapies?
